Daily Bulletin

Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

SYDNEY, Dec. 10, 2024 /PRNewswire/ -- Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF)1. The interim results2 suggest that SNT-5505...

Read more: Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis

Business News

How to Choose the Right Props for Your Brisbane Construction Site

The choice of props affects the safety and efficiency of construction in Brisbane. The demand for the project should first be assessed, including the environmental restrictions and the loads that ...

Daily Bulletin - avatar Daily Bulletin

What Is Pre-Qualification and Why Should Australian Contractors Care?

Pre-qualification is the process that ensures contractors meet key standards and legal requirements before being considered for projects. While it started in construction, it’s now used across indus...

Jessica Jorgenson - avatar Jessica Jorgenson

Comprehensive Guide to Site Surveys and Surveying Companies in Perth

A site survey is among the first and most crucial steps in property development projects and land use planning. They are a detailed compilation of data on any piece of land, and they contain informati...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals